此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes (Col-DM)

2026年9月20日 更新者:Tan Tock Seng Hospital

The Role of Colchicine in Preventing Atherosclerotic Cardiovascular Disease in Type 2 Diabetes (Col-DM Study)

This study will test whether a low-cost anti-inflammatory medicine called colchicine can help protect the blood vessels of people with type 2 diabetes. Diabetes speeds up hardening of the arteries (atherosclerosis), partly because of ongoing low-grade inflammation. Colchicine has already been shown to help prevent heart attacks and strokes in people who already have heart disease; this study looks at whether it can also help prevent early blood vessel damage before heart disease develops. Around 300 adults with type 2 diabetes will be randomly assigned to take colchicine or a placebo (dummy pill) once daily for 24 weeks, in addition to their usual diabetes and heart-risk medications. Neither participants nor the study team will know who is taking colchicine or placebo. The main measurement will be the change in the thickness of the wall of the neck (carotid) artery, measured by ultrasound, which is an early sign of blood vessel disease. The study will also look at markers of inflammation in the blood, blood vessel stiffness and function, and changes in the gut bacteria.

研究概览

详细说明

Cardiovascular disease remains the leading cause of death in T2DM, occurring earlier and at substantially higher rates than in the general population. Despite optimisation of conventional risk factors, residual cardiovascular risk remains high, with chronic low-grade inflammation driven by dysregulated neutrophil activity recognised as a key contributor. Patients with T2DM exhibit a distinct pro-inflammatory neutrophil phenotype characterised by increased neutrophil extracellular trap (NET) formation, heightened endothelial adherence, and altered rolling kinetics, which correlates with impaired vascular function and subclinical atherosclerosis.

Colchicine inhibits neutrophil activation, migration, and NET formation, and has demonstrated efficacy in secondary cardiovascular prevention in large randomised trials. Evidence in primary prevention, particularly in T2DM, remains limited. Col-DM takes a precision medicine approach, hypothesising that colchicine's benefit will be concentrated among T2DM patients with a high-risk inflamed neutrophil signature rather than being uniform across the broader population.

Col-DM is a 24-week, parallel-group, Phase 2 randomised controlled trial. Adults with T2DM and no prior atherosclerotic cardiovascular disease are randomised 1:1 to colchicine 0.5 mg daily or matched placebo, stratified by neutrophil inflammatory phenotype classified using a microfluidic organ-on-chip platform. The primary outcome is progression of carotid intima-media thickness (CIMT), estimated overall and separately within each neutrophil-signature stratum. Secondary outcomes cover vascular function, inflammatory and oxidative stress biomarkers, and thrombotic potential. Gut microbiome composition is examined as an exploratory outcome. All outcome measures are estimated overall and separately within each neutrophil-signature stratum. Safety is monitored by an independent Data and Safety Monitoring Committee.

研究类型

介入性

注册 (估计的)

300

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Singapore
      • Singapore、Singapore、新加坡、308433
        • 招聘中
        • Tan Tock Seng Hospital
        • 接触:
        • 首席研究员:
          • Rinkoo Dalan, MD, PhD
        • 副研究员:
          • Ying Jie Chee, MD
        • 副研究员:
          • Rupesh Agrawal, M Med (Ophth), MD (Research)
        • 副研究员:
          • Huiling Liew, MD
        • 副研究员:
          • Ying Shan Lee, MBBS
        • 副研究员:
          • Eugene Fan, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • T2DM on stable diabetes medications (no change in last 3 months)
  • At least one other comorbidity of hypertension, dyslipidaemia and/or obesity (BMI ≥27), with no previous history of ASCVD
  • Able to provide informed consent

Exclusion Criteria:

  1. Recent hospitalization or acute infections within last 2 weeks.
  2. Current Treatment with corticosteroids or immunosuppressive agents
  3. Pre-existing malignancies or other terminal conditions with limited prognosis
  4. Pregnancy
  5. Breastfeeding
  6. Inability to provide written consent
  7. Renal impairment (eGFR< 60ml/min)
  8. Liver cirrhosis or ALT/AST >3x ULN
  9. Pharmacogenomics indicative of adverse effects
  10. Hypersensitivity to the active substance or to the following excipients: Lactose, Maize starch, Sodium laurilsulfate, Magnesium stearate
  11. Known blood dyscrasia
  12. Women of childbearing age who are keen to conceive in the next 1 year
  13. Taking a strong P-glycoprotein inhibitor (e.g. cyclosporine, ranolazine) or a strong CYP3A4 inhibitor
  14. Known myositis with raised creatine kinase with statins (statin myopathy).
  15. Gout attack within the last 1 year
  16. Currently taking Aspirin
  17. Taking any oral contraceptives

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Colchicine

Colchicine 0.5 mg orally once daily for 24 weeks, in addition to usual risk-factor-based therapy

For 24 weeks

安慰剂比较:Placebo

Matched placebo orally once daily for 24 weeks, in addition to usual risk-factor-based therapy

Matched placebo tablets (identical in size, shape, taste, and packaging to colchicine), once daily, for 24 weeks

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from Baseline in Mean-Maximum Carotid Intima-Media Thickness (Mean-Maximum CIMT)
大体时间:Baseline and 24 weeks

Mean-maximum CIMT is defined as the average of the maximum CIMT values obtained from the far wall of the left and right common carotid arteries, each derived from six measurements taken across three projections (lateral, anterior, and posterior) at 1 cm proximal to the carotid bifurcation, measured by high-resolution B-mode carotid ultrasonography.

Baseline and 24 weeks

次要结果测量

结果测量
措施说明
大体时间
Change from Baseline in Mean Carotid Intima-Media Thickness (avgCIMT)
大体时间:Baseline and 24 weeks

Mean CIMT (avgCIMT) is defined as the average of all twelve individual IMT measurements obtained from the far wall of the left and right common carotid arteries (six measurements per side), measured by high-resolution B-mode carotid ultrasonography.

Baseline and 24 weeks
Change from Baseline in Carotid Plaque Volume
大体时间:Baseline and 24 weeks

Carotid plaque volume is measured using 3D plaque volume software following standard acquisition protocol in participants with identified carotid plaque on ultrasonography.

Baseline and 24 weeks
Change from Baseline in Endothelial Function (Flow-Mediated Dilation)
大体时间:Baseline and 24 weeks

Endothelial function is assessed by flow-mediated dilation (FMD) of the brachial artery using high-resolution ultrasound, expressed as the percentage change in brachial artery diameter following reactive hyperaemia.

Baseline and 24 weeks
Change from Baseline in Microvascular Reactivity (Reactive Hyperaemia Index)
大体时间:Baseline and 24 weeks

Microvascular reactivity is assessed by the reactive hyperaemia index (RHI) measured using EndoPAT, a non-invasive device that quantifies peripheral arterial tone response to forearm occlusion.

Baseline and 24 weeks
Change from Baseline in Arterial Stiffness (Pulse Wave Velocity)
大体时间:Baseline and 24 weeks

Arterial stiffness is assessed by carotid-femoral pulse wave velocity (PWV) measured using SphygmoCor XCEL, a validated applanation tonometry-based device.

Baseline and 24 weeks
Change from Baseline in Arterial Stiffness (Cardio-Ankle Vascular Index)
大体时间:Baseline and 24 weeks

Arterial stiffness is additionally assessed by the cardio-ankle vascular index (CAVI), a measure of arterial stiffness from the origin of the aorta to the ankle that is less dependent on blood pressure at the time of measurement.

Baseline and 24 weeks
Change from Baseline in Skin Advanced Glycation End Products (Skin Autofluorescence)
大体时间:Baseline and 24 weeks

Tissue advanced glycation end product (AGE) accumulation is measured non-invasively using the AGE Reader, which quantifies skin autofluorescence using ultraviolet light excitation.

Baseline and 24 weeks
Change from Baseline in Retinal Layer Thickness (Optical Coherence Tomography)
大体时间:Baseline and 24 weeks

Retinal layer thickness is measured by optical coherence tomography (OCT) as a surrogate of retinal and systemic microvascular health.

Baseline and 24 weeks
Change from Baseline in Retinal Microvascular Density (Optical Coherence Tomography Angiography)
大体时间:Baseline and 24 weeks

Retinal microvascular density is measured by optical coherence tomography angiography (OCTA) as a surrogate of systemic microvascular health.

Baseline and 24 weeks
Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
大体时间:Baseline and 24 weeks

Serum high-sensitivity C-reactive protein (hsCRP) is measured as a marker of systemic inflammation.

Baseline and 24 weeks
Change from Baseline in Interleukin-6 (IL-6)
大体时间:Baseline and 24 weeks

Plasma interleukin-6 (IL-6) is measured as a marker of systemic inflammation and cytokine activity.

Baseline and 24 weeks
Change from Baseline in Plasminogen Activator Inhibitor-1 (PAI-1)
大体时间:Baseline and 24 weeks

Plasma plasminogen activator inhibitor-1 (PAI-1) is measured as a marker of impaired fibrinolysis and endothelial dysfunction.

Baseline and 24 weeks
Change from Baseline in Cell-Free DNA (NETosis Marker)
大体时间:Baseline and 24 weeks

Plasma cell-free DNA is measured as a marker of neutrophil extracellular trap (NET) formation and neutrophil-mediated inflammatory activity.

Baseline and 24 weeks
Change from Baseline in Citrullinated Histone H3 (NETosis Marker)
大体时间:Baseline and 24 weeks

Plasma citrullinated histone H3 is measured as a specific marker of neutrophil extracellular trap (NET) formation and NETosis.

Baseline and 24 weeks
Change from Baseline in E-selectin
大体时间:Baseline and 24 weeks

Plasma E-selectin is measured as a marker of endothelial activation and inflammation.

Baseline and 24 weeks
Change from Baseline in Intercellular Adhesion Molecule-1 (ICAM-1)
大体时间:Baseline and 24 weeks

Plasma ICAM-1 is measured as a marker of endothelial activation and leucocyte adhesion.

Baseline and 24 weeks
Change from Baseline in Vascular Cell Adhesion Molecule-1 (VCAM-1)
大体时间:Baseline and 24 weeks

Plasma VCAM-1 is measured as a marker of endothelial activation and vascular inflammation.

Baseline and 24 weeks
Change from Baseline in Oxidative Stress Index
大体时间:Baseline and 24 weeks

An integrated oxidative stress index is derived from nuclear magnetic resonance (NMR)-based redox profiling of plasma and erythrocytes, providing a composite measure of systemic oxidative stress.

Baseline and 24 weeks
Change from Baseline in Thrombotic Potential (Clot Waveform Analysis)
大体时间:Baseline and 24 weeks

Clot waveform analysis is performed to characterise the kinetics of clot formation and fibrinolysis in plasma as a measure of overall thrombotic potential.

Baseline and 24 weeks
Change from Baseline in Von Willebrand Factor Antigen (VWF:Ag)
大体时间:Baseline and 24 weeks

Plasma von Willebrand factor antigen (VWF:Ag) is measured as a marker of endothelial activation and thrombotic risk.

Baseline and 24 weeks
Change from Baseline in Von Willebrand Factor Activity (VWF:Act)
大体时间:Baseline and 24 weeks

Plasma von Willebrand factor activity (VWF:Act) is measured as a functional marker of thrombotic risk and platelet adhesion capacity.

Baseline and 24 weeks
Change from Baseline in Factor VIII
大体时间:Baseline and 24 weeks

Plasma factor VIII levels are measured as a marker of coagulation activation and thrombotic potential.

Baseline and 24 weeks
Change from Baseline in Thrombin Generation
大体时间:Baseline and 24 weeks

Thrombin generation is measured using a calibrated automated thrombogram to assess overall coagulation potential and thrombotic risk.

Baseline and 24 weeks
Change from Baseline in Oxidised LDL (Ox-LDL)
大体时间:Baseline and 24 weeks

Plasma oxidised LDL (Ox-LDL) is measured by nuclear magnetic resonance (NMR) spectroscopy as a marker of lipid oxidation and atherogenic risk.

Baseline and 24 weeks
Change from Baseline in Atherogenic Lipid Subfractions
大体时间:Baseline and 24 weeks

Atherogenic lipid subfractions are characterised by nuclear magnetic resonance (NMR) spectroscopy, providing detailed lipoprotein particle profiling beyond standard lipid panels.

Baseline and 24 weeks

其他结果措施

结果测量
措施说明
大体时间
Change from Baseline in Gut Microbiome Composition
大体时间:Baseline and 24 weeks

Gut microbiome composition is characterised from stool samples by metagenomic sequencing, to examine whether colchicine-associated shifts in microbial composition relate to treatment response.

Baseline and 24 weeks
Change from Baseline in Plasma Metabolite Profile (Metabolomics)
大体时间:Baseline and 24 weeks

As an exploratory analysis, plasma metabolomic profiling will be performed on stored blood samples to characterise changes in the metabolite profile over 24 weeks.

Baseline and 24 weeks
Incidence of Adverse Events and Serious Adverse Events
大体时间:From randomisation through 24 weeks

Safety is assessed by the incidence of adverse events (AEs) and serious adverse events (SAEs), defined per standard regulatory criteria, ascertained at each study visit and telephone contact, and adjudicated by an independent Data and Safety Monitoring Committee.

From randomisation through 24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Rinkoo Dalan, MD, PhD、Tan Tock Seng Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年7月24日

初级完成 (估计的)

2027年7月31日

研究完成 (估计的)

2027年7月31日

研究注册日期

首次提交

2026年9月6日

首先提交符合 QC 标准的

2026年9月20日

首次发布 (实际的)

2026年9月24日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月20日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The individual participant data will not be publicly shared due to patient confidentiality restrictions and institutional data governance requirements. Researchers seeking access for secondary analyses may contact the study team to discuss feasibility, subject to a formal data sharing or research collaboration agreement with the institution.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅